Shares of Green Thumb Industries have edged down slightly in the months since a brief run-up in April, but investors are still weighing whether the company is undervalued based on fundamentals rather than cannabis-sector sentiment. The Chicago-based multistate operator continues to differentiate itself from many peers by sustaining profitability and by pursuing a licensing renegotiation that management said can improve operating leverage.
Key takeaways
-
Green Thumb Industries has pulled back modestly after last April’s short-lived surge, even as the stock has held up relatively well.
-
A major catalyst is a renegotiated licensing agreement tied to Rythm’s trademarks, shifting Green Thumb to a flat fee structure.
-
The company has reported GAAP profitability since 2020, supporting the case that it is further along than many cannabis peers.
-
Additional upside drivers include a conditional license for Texas’ upcoming legalized medical cannabis market and ongoing share buybacks.
-
Investors looking for exposure to eventual federal clarity may view U.S. multistate operators as the stronger pathway compared with Canada-focused players.
What drives the bull case for Green Thumb
Green Thumb is part of a smaller group of U.S. multistate operators, or MSOs, that own and operate licensed cannabis businesses at the state level. While Canada-based cannabis operators have faced persistent challenges reaching sustained profitability, Green Thumb has reported GAAP profitability since 2020, according to the article.
Beyond its earnings record, the company’s most notable near-term catalyst involves its relationship with Rythm. Early in the year, Green Thumb renegotiated its licensing deal with 50%-owned Rythm, shifting from paying a percentage-based licensing fee to paying a flat licensing fee for Rythm’s trademarks. The article argues that this structure could increase operating leverage and translate into stronger earnings growth if volumes and margins hold up.
Additional catalysts and capital returns
The article also points to Green Thumb’s progress on market access and capital allocation. It said the company has received a conditional license allowing it to operate within Texas’ upcoming legalized medical cannabis market, which could expand its operating footprint as regulations come online.
On the shareholder side, Green Thumb has continued to buy back stock. The article states the company recently increased its share repurchase program ceiling by $100 million, described as about 6% of its total share count. Buybacks can support per-share metrics, particularly if management believes shares are trading at an attractive level relative to expected earnings power.
Even so, valuation remains part of the debate. The article notes the stock is trading at 38.8 times forward earnings, implying that investors expecting renewed gains may need continued proof of margin and earnings momentum rather than relying solely on regulatory optimism.
How the market appears to be interpreting the story
According to the article, the stock’s modest pullback after April’s brief surge does not necessarily mean the market has fully reflected the company’s fundamentals. Instead, the author frames Green Thumb as a stronger cannabis vehicle for investors bullish on eventual regulatory clarity around U.S. federal law and the commercial sale of cannabis products.
That framing also highlights a key sector distinction: the market has historically rewarded companies with demonstrated profitability and scalable U.S. operations more consistently than it has rewarded many early-stage or Canada-focused producers. By combining profitability since 2020 with licensing-related operating leverage and incremental expansion opportunities such as Texas, the article suggests investors may view Green Thumb as positioned to outperform peers if the regulatory landscape improves.
Bigger picture: why MSOs are the focus
The article’s core investment logic is that multistate operators may be better positioned to benefit from a gradual transition toward clearer federal rules and broader commercial markets. It contrasts Green Thumb with Canada-based operators, arguing that the latter face limits on entering the U.S. and continued pressure to reach sustained profitability.
For investors, the implication is that the next leg of movement in cannabis equities may depend less on broad sector headlines and more on company-specific catalysts—such as earnings durability, cost structure, licensing economics, and the timing of new state market launches—while U.S. federal policy remains a swing factor.
Going forward, investors in Green Thumb may want to watch for evidence that the Rythm licensing change translates into improved margins and earnings growth, along with updates on Texas’ medical market rollout. With ongoing share repurchases and any future company disclosures related to regulatory progress, the company’s next earnings reports and guidance will likely be the clearest checkpoints for whether the profitability and leverage story is strengthening.
